DALLAS, October 13, 2014 /PRNewswire/ --
The Global and China DNA Sequencing Industry Research Report, 2014-2017 says with the advancement of DNA sequencing technology and dramatic decline in sequencing costs, DNA sequencing is increasingly showing its market potential in noninvasive detection, disease diagnosis, and personalized treatment. In 2013, the market size of global DNA sequencing (including equipment and consumables, service and workflow, etc.) approximated USD4.6 billion, up around 26% from the previous year. It is projected that by 2017 this figure will reach USD10.096 billion, exceeding USD10 billion for the first time. Complete report is available at http://www.chinamarketresearchreports.com/114929.html .
The upstream sectors of DNA sequencing industry are extremely robust, with the global market dominated by the second-generation DNA sequencing enterprises including Illumina, Thermo Fisher Scientific (through Life Technologies), Roche and the third-generation sequencing enterprises such as Pacific Biosciences. A review of these giants' development history shows that mergers and acquisitions are the main driving forces behind the great market power. In February 2014, Roche acquired Life Technologies for USD13.6 billion, making it the industry giant second only to Illumina.
In China, the upstream sectors of DNA sequencing industry are virtually monopolized by foreign giants. BGI is the leader in China's DNA sequencing service, and its second-generation DNA sequencers top the global chart in number. However, two of its sequencers-HiSeq 2000 and Ion Proton were entirely from Illumina and Life Technologies. In March 2013, BGI acquired Complete Genomics, a sign that BGI formally ventured into the upstream sectors of DNA sequencing industry. In June 2014, BGI's two products-BGISEQ-1000 and BGISEQ-100 became the first second-generation DNA sequencers registered in China.
Companies profiled in Global and China DNA Sequencing Industry Research Report, 2014-2017 include Illumina, Thermo Fisher Scientific, BGI, Roche, Qiagen, Pacific Biosciences, Sequenom, DAAN Gene, Agilent Technologies, Berry Genomics, Hunan China Sun Pharmaceutical Machinery and Jilin Zixin Pharmaceutical Industrial. Order a copy of this research at http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114929 .
It is expected, however, that within the next five years the weak position of Chinese enterprises in upstream sectors will remain unchanged except for the epic M&A. Global and China DNA Sequencing Industry Research Report 2014-2017 majorly focuses on the following information and data: Features, cost, etc. of DNA sequencing technology; Major M&As, genetic database, market size and structure, etc. of global DNA sequencing industry; Development, industry policies, market structure and prospects, etc. of DNA sequencing industry in China; Operation, DNA sequencing business, etc. of 12 enterprises at home and abroad.
DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a broad range of fields, including medicine, biology, geology, and agriculture. Ever since 1975, DNA sequencing technology has been through four generations, but the fourth-generation technology-Nanopore sequencing is still under development. Due to technologies and costs, the second-generation high-throughput sequencers are the mainstream sequencing platform around the world, with its total number occupying over 95% of next-generation DNA sequencers worldwide.
Partial List of Charts provided in Global and China DNA Sequencing Industry Research Report, 2014-2017 include:
Worldwide Top 30 Countries or Regions with Next-generation DNA Sequencer by Number of Centers as of Sept. 2014
Global Next-Generation DNA Sequencer Distribution by Center as of Sept. 2014
Global Next-Generation DNA Sequencer Market Structure by Product as of Sept. 2014
Global Next-Generation DNA Sequencing Market Structure by Enterprise as of Sept. 2014
Global Next-Generation DNA Sequencing Market Structure by Number of Generation as of Sept. 2014
Global Next-Generation DNA Sequencer Distribution by Region as of Sept. 2014
Worldwide Top 30 Countries or Regions by Number of Next-Generation DNA Sequencers as of Sept. 2014
Next-Generation DNA Sequencer Market Structure of Global Genome Centers by Product as of Sept. 2014
Top 10 Global Genome Centers by Number of Next-Generation DNA Sequencers as of Sept. 2014
Global DNA Sequencing Market Structure, 2017E
China Next-generation DNA Sequencer Proportion in Global Market as of Sept. 2014
Illumina's DNA Sequencers and Consumables (by Type) and Their Application
Revenue and Net Income of Illumina, 2014-2017E
Revenue and Net Income of Thermo Fisher Scientific, 2014-2017E
R&D Costs and % of Total Revenue of Agilent Technologies, 2009-2014
Revenue and Net Income of DAAN Gene, 2014-2017E
Major Events of Berry Genomics, 2010-2014
DNA Sequencing Products of Berry Genomics
Revenue and Net Income of Hunan Honghao Gene, 2012-2014
Hunan Honghao Gene's Medical Devices Registered Based on Gene Chip, 2012-2014
Revenue and Net Income of Jilin Zixin Pharmaceutical Industrial, 2009-2014
Development History of DNA Sequencing of Jilin Zixin Pharmaceutical Industrial, 2010-2014
Comprehensive Table of Contents and more on this DNA sequencing industry research report are available at http://www.chinamarketresearchreports.com/114929-toc.html .
The Global and China Stem Cell Industry Report, 2014-2017 is spread across 105 pages and says the stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Companies like Cryo-Cell International, Esperite, Zhongyuan Union Stem Cell Bioengineering, Golden Meditech, LifeCell International, Cryosite, NeoStem, Mesoblast, MEDIPOST, Beike Biotechnology, Osiris Therapeutics, Orthofix International, Cytori Therapeutics, Athersys, Pluristem Therapeutics, StemCells, Advanced Cell Technology, Celgene, Vitro Biopharma, Reneuron, Tigenix, Cellular Biomedicine Group, Inc. (CBMG), Opexa Therapeutics, ZhongKeBiopharm and Cyagen Biosciences are profiled in this research available at http://www.chinamarketresearchreports.com/114908.html .
China Market Research Reports is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on:
Google Plus / G+: https://plus.google.com/+Chinamarketresearchreports/posts
SOURCE China Market Research Reports